Evidence map›Paper›PMID 19159483›Full record

ArticleBMC public health2009

Cost-effectiveness of Rotavirus vaccination in Vietnam.

Sun-Young Kim, Sue J Goldie, Joshua A Salomon

3 registry-linked trialsOpen access · goldAbstract readEvaluation Study
In one paragraph

Article in BMC public health, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 3 registered trials, which are not on this map. Cited by 29 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
29citing papers in PubMed, 4 pooled it
4.0field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT01375907 phase1completednot on this map

A Phase 1 Study to Evaluate Safety and Reactogenicity of a Vietnamese Rotavirus Vaccine (Rotavin-M1 at 10e6.3FFU/Dose) Among Healthy Adults in Vietnam

TypeinterventionalSponsorNational Institute of Hygiene and Epidemiology, VietnamRan2009 to 2009Enrolled29ConditionsDiarrhea, Vomit, Fever, NauseaArmsRotavin
NCT01377571 phase2completednot on this map

A Phase II, Randomized, Double-blind, Vaccine-controlled Dose-escalating Study to Evaluate the Immunogenicity, Reactogenicity and Safety of Oral Live Attenuated Human Rotavirus (HRV) Vaccine (Rotavin-M1) in Healthy Infants in Vietnam

TypeinterventionalSponsorNational Institute of Hygiene and Epidemiology, VietnamRan2009 to 2010Enrolled200ConditionsDiarrhea, Fever, Nausea, VomitArmsRotarix
NCT01502969 phase2 / phase3completednot on this mapstarted 2010, after this paper: background citation

A Phase 2b Study of Rotavin-M1 Vaccine in Vietnamese Children

TypeinterventionalSponsorNational Institute of Hygiene and Epidemiology, VietnamRan2010 to 2011Enrolled799ConditionsDiarrhea, Fever, Nausea, VomitArmsRotavin-M1, cell culture medium in absence of virus
3 · Its place in the literature

Who cites it

29 citing papers in PubMed, 4 syntheses or guidelines pooled it, 57 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Systematic review of the economic value of diarrheal vaccines.Human vaccines & immunotherapeutics · 2014
    Pooled it
  4. Pooled it
  5. An overview of the perspectives used in health economic evaluations.Cost effectiveness and resource allocation : C/E · 2024
    Review
  6. Article
  7. Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. The cost effectiveness of rotavirus vaccination in Iran.Human vaccines & immunotherapeutics · 2016
    Article
  14. Article
  15. Review
  16. Article
  17. Article
  18. Article
  19. Review
  20. Prevalence and molecular genotyping of group a rotaviruses in Iranian children.Indian journal of virology : an official organ of Indian Virological Society · 2012
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 2 institutions in 1 country.

Sun-Young KimDepartment of Health Policy and Management, Harvard School of Public Health, Boston, MA, USA. sykim@hsph.harvard.edu
Sue J Goldie
Joshua A Salomon
Harvard Global Health Institute · USHarvard University · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundRotavirus is the most common cause of severe diarrhea leading to hospitalization or disease-specific death among young children. New rotavirus vaccines have recently been approved. Some previous studies have provided broad qualitative insights into the health and economic consequences of introducing the vaccines into low-income countries, representing several features of rotavirus infection, such as varying degrees of severity and age-dependency of clinical manifestation, in their model-based analyses. We extend this work to reflect additional features of rotavirus (e.g., the possibility of reinfection and varying degrees of partial immunity conferred by natural infection), and assess the influence of the features on the cost-effectiveness of rotavirus vaccination.

methodsWe developed a Markov model that reflects key features of rotavirus infection, using the most recent data available. We applied the model to the 2004 Vietnamese birth cohort and re-evaluated the cost-effectiveness (2004 US dollars per disability-adjusted life year [DALY]) of rotavirus vaccination (Rotarix) compared to no vaccination, from both societal and health care system perspectives. We conducted univariate sensitivity analyses and also performed a probabilistic sensitivity analysis, based on Monte Carlo simulations drawing parameter values from the distributions assigned to key uncertain parameters.

resultsRotavirus vaccination would not completely protect young children against rotavirus infection due to the partial nature of vaccine immunity, but would effectively reduce severe cases of rotavirus gastroenteritis (outpatient visits, hospitalizations, or deaths) by about 67% over the first 5 years of life. Under base-case assumptions (94% coverage and $5 per dose), the incremental cost per DALY averted from vaccination compared to no vaccination would be $540 from the societal perspective and $550 from the health care system perspective.

conclusionIntroducing rotavirus vaccines would be a cost-effective public health intervention in Vietnam. However, given the uncertainty about vaccine efficacy and potential changes in rotavirus epidemiology in local settings, further clinical research and re-evaluation of rotavirus vaccination programs may be necessary as new information emerges.

Indexed as

Analysis of VarianceChild, PreschoolCost-Benefit AnalysisDisability EvaluationHumansInfantMarkov ChainsModels, EconomicQuality-Adjusted Life YearsRotavirus InfectionsRotavirus VaccinesVaccines, AttenuatedVietnamRIX4414 vaccineRotavirus VaccinesVaccines, Attenuated

Identifiers

PMID19159483
PMCPMC2663769
OpenAlexW2122685289

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.